Open access
Open access
Powered by Google Translator Translator

Endocrinology

RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.

22 Jul, 2021 | 11:08h | UTC

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology

Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology

 


Case report: Treatment-induced neuropathy of diabetes related to abrupt glycemic control.

21 Jul, 2021 | 10:33h | UTC

Treatment-induced neuropathy of diabetes related to abrupt glycemic control – Canadian Medical Association Journal

 

Commentaries on Twitter

 


UK National Food Strategy: Tax sugar and salt and prescribe veg, report says.

21 Jul, 2021 | 10:30h | UTC

National Food Strategy: Tax sugar and salt and prescribe veg, report says – BBC

Report: National Food Strategy Independent Review

Related: Fiscal policies for diet and the prevention of noncommunicable diseases – World Health Organization (free) AND  The Lancet taskforce on NCDs and economics (free series and commentaries) To improve global health, tax the things that are killing us – Financial Times (free policies, articles and commentaries) AND Reducing cardiovascular disease burden through targeted dietary policies (free study and commentaries) AND Fiscal policies for the prevention of diseases (free study and commentary) AND The potential impact of food taxes and subsidies on cardiovascular disease and diabetes burden and disparities (free)

 


RCT: Once weekly semaglutide 2.0 mg vs. 1.0 mg in patients with type 2 diabetes – Mean change in HbA1c from baseline was −2.2 percentage points with 2.0 mg vs. −1.9 percentage points with 1.0 mg; mean change in bodyweight from baseline was −6.9 kg with 2.0 mg vs. −6.0 kg with 1.0 mg.

20 Jul, 2021 | 10:09h | UTC

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial – The Lancet Endocrinology & Diabetes (link to abstract – $ for full-text)

 


M-A: benefit-to-harm balance of statins in primary prevention of cardiovascular disease generally favorable.

18 Jul, 2021 | 23:16h | UTC

News release: New study suggests benefit-to-harm balance of statins for healthy adults ‘generally favorable’ – BMJ

Original study: Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses – The BMJ

 

Commentary on Twitter

 


Review: Glucocorticoid induced adrenal insufficiency.

18 Jul, 2021 | 23:15h | UTC

Glucocorticoid induced adrenal insufficiency – The BMJ

 

Commentary on Twitter

 


Body-mass index and diabetes risk in 57 low-income and middle-income countries – “Optimal BMI thresholds for diabetes screening ranged from 23·8 kg/m2 among men in east, south, and southeast Asia to 28·3 kg/m2 among women in the Middle East and north Africa and in Latin America and the Caribbean”.

18 Jul, 2021 | 23:10h | UTC

Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults – The Lancet (link to abstract – $ for full-text)

Related: Study shows BMI cut-offs for obesity and diabetes risk do not work for non-white populations. AND Study: Certain Racial/Ethnic Groups More Likely to Have Diabetes and Prediabetes at Lower Weights

 


Cohort study: Increased risk of long-term risk of anemia after bariatric surgery – Compared with the control group, the incidence of anemia was higher in the gastric bypass group (HR 5.05), the vertical-banded gastroplasty group (HR 2.67), and the gastric banding group (HR 2.76).

15 Jul, 2021 | 09:10h | UTC

Long-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

 


Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.

14 Jul, 2021 | 10:56h | UTC

SGLT2 Inhibitors and GLP-1 Receptor Agonists: Indications – American College of Cardiology

Original review: SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications – The Lancet (link to abstract – $ for full-text)

Related guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

 


AHA Scientific Statement: Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse.

12 Jul, 2021 | 01:43h | UTC

Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association – Circulation

News release: Discrimination, stress linked to poorer heart health in transgender, gender diverse adults – American Heart Association

 


Review: Lipoprotein(a) and cardiovascular diseases.

12 Jul, 2021 | 01:33h | UTC

Lipoprotein(a) and Cardiovascular Diseases – JAMA (free for a limited period)

 


ADA Draft Consensus Report: Management of Type 1 Diabetes in Adults.

8 Jul, 2021 | 09:04h | UTC

The Management of Type 1 Diabetes in Adults — A Consensus Report by the ADA and EASD

Commentaries: ADA/EASD Draft Guidance Aims to Bring Adults With Type 1 Diabetes Out of Shadows – Medscape (free registration required) AND New consensus report on adults with type 1 diabetes focuses on individualised care – Diabetes Times

Related: Guideline: ADA 2021 Standards of Medical Care in Diabetes

 


Review: Dietary recommendations for prevention of atherosclerosis.

8 Jul, 2021 | 09:03h | UTC

Dietary recommendations for prevention of atherosclerosis – Cardiovascular Research

News Release: What should I eat to avoid heart disease? – European Society of Cardiology

Commentary: Plant-Based Diet Best for Your Heart – HealthDay

 


RCT: Cardiovascular and renal outcomes with Efpeglenatide (a GLP-1 receptor agonist) in Type 2 Diabetes.

7 Jul, 2021 | 08:45h | UTC

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes – New England Journal of Medicine

Commentary: Efpeglenatide Cuts Risk of CV Events and Kidney Disease in High-Risk T2D Patients, Regardless of SGLT2 Status – AJMC

 


WHO launches List of Priority Medical Devices for management of cardiovascular diseases and diabetes.

6 Jul, 2021 | 10:09h | UTC

News release: WHO launches List of Priority Medical Devices for management of cardiovascular diseases and diabetes – World Health Organization

Guidance: WHO list of priority medical devices for management of cardiovascular diseases and diabetes – World Health Organization

 

Commentary on Twitter

 


M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.

30 Jun, 2021 | 10:08h | UTC

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis – EClinicalMedicine

 


RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

28 Jun, 2021 | 09:46h | UTC

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet

 


RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.

28 Jun, 2021 | 09:45h | UTC

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D – MedPage Today (free registration required)

 


Guideline | Perimenopause and Postmenopause – Diagnosis and Interventions.

28 Jun, 2021 | 09:32h | UTC

Perimenopause and Postmenopause – Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020) – Geburtshilfe Frauenheilkd

 


Perspective | Why are people with obesity more vulnerable to COVID?

25 Jun, 2021 | 10:21h | UTC

Why Are People with Obesity More Vulnerable to COVID? – Scientific American

 


Viewpoint | Progress in Pharmacotherapy for Obesity.

24 Jun, 2021 | 09:46h | UTC

Progress in Pharmacotherapy for Obesity – JAMA (free for a limited period)

See also: Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment – JAMA (free for a limited period)

Audio clinical review: Semaglutide for Weight Loss

 


Cohort study: no association was found between statin therapy and cognitive decline or incident dementia in older adults.

23 Jun, 2021 | 10:14h | UTC

Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults – Journal of the American College of Cardiology

Commentaries: Statin Therapy Not Associated With Cognitive Decline, Dementia in Older Adults, Study Says – American College of Cardiology AND Effect of Statins on Cognitive Decline and Dementia in Older Adults – American College of Cardiology

 


Expert analysis | The global prevention of cardiovascular disease among people living with diabetes: leading with heart.

23 Jun, 2021 | 10:13h | UTC

The Global Prevention of Cardiovascular Disease Among People Living with Diabetes: Leading with Heart – American College of Cardiology

Original publication and resources: The Global Diabetes Compact – World Health Organization

See also: The WHO Global Diabetes Compact: a new initiative to support people living with diabetes – The Lancet Diabetes & Endocrinology (free registration required)

 


Study shows overuse of levothyroxine in patients with subclinical hypothyroidism despite evidence of no benefit.

22 Jun, 2021 | 09:57h | UTC

Levothyroxine Use in the United States, 2008-2018 (free for a limited period)

Editorial: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine – JAMA Internal Medicine (free for a limited period)

Related: RCT: Levothyroxine does not reduce the risk of developing depressive symptoms in older adults with subclinical hypothyroidism (studies and guidelines on the subject)

 


Expert analysis: the ever-growing role of coronary artery calcium in primary prevention.

22 Jun, 2021 | 09:54h | UTC

The Ever-Growing Role of Coronary Artery Calcium in Primary Prevention – American College of Cardiology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.